ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that that it will display its portfolio of clinical resuscitation products including the LifeVest® Wearable Defibrillator, along with sudden cardiac death (SCD) education and screening tools, in Booth #1417 at the 2014 American College of Cardiology Annual Scientific Session and Expo, March 29-31 in Washington, DC.
The LifeVest will be discussed during the following presentations:
• Negar Salehi, MD, Sparrow Hospital, Lansing, Mich., will present “Experience with Wearable Cardioverter Defibrillator in Non-Ischemic Cardiomyopathy: A National Database Analysis,” Sunday, March 30, 11:00 am., Presentation #921-04, Room 145B.
• Nicole R. Bianco, PhD, ZOLL, will present “Survivors of Sudden Cardiac Arrest in the Presence of Myocardial Infarction: Secondary Protection with the Wearable Cardioverter Defibrillator,” Sunday, March 30, 9:45 am., Presentation #1199M-360A, Hall C.
An Industry-Expert Theater event focused on the LifeVest entitled “You Got Them Through the PCI. Now What?” will be presented by J. Jeffrey Marshall, MD, FSCAI, FACC, Northeast Georgia Medical Center, Saturday, March 29, 2014, 3:45-4:45 pm., in Expo Hall #2353.
The LifeVest protects patients at risk for SCD. It is used to protect a wide range of patients, including recent myocardial infarction, or following coronary revascularization. One-in-five post-acute myocardial infarction (AMI) patients have been shown to be at high risk of dying after percutaneous coronary intervention (PCI).i The majority of mortality in AMI patients post-PCI occurs in the first three months one out of every 10 high risk patients die, with about 60% of this mortality due to SCD.i, ii The LifeVest gives physicians time to optimize medical therapy and assess a patient’s long-term risk for sudden death.
The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCD. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.
The LifeVest is covered by most health plans in the United States, including commercial, state, and federal plans.
Additional products on display from ZOLL include:
• The R Series® Code-Ready Defibrillators are designed to extend “Simple, Smart and Ready” defibrillation to every hospital department through advanced, cost-effective solutions for resuscitation. The original R Series ALS, and the R Series Plus, which has both AED and ALS capabilities at the touch of a button, offer See-Thru CPR®, a breakthrough technology that minimizes the duration of pauses in CPR to enable rescuers to see the underlying rhythm. Like all ZOLL defibrillators, the R Series also features Real CPR Help® audio and visual feedback for the correct depth and rate of chest compressions.
• Intravascular Temperature Management (IVTM™) technology offers health care providers the power and control they need to rapidly, safely, and effectively manage the core body temperature of critically ill or surgical patients. The Thermogard XP® delivers accurate, easy-to-use, and cost-effective control for both cooling and warming applications.
About ZOLL Medical Corporation
ZOLL Medical Corporation (zoll.com), an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care.
About Asahi Kasei
The Asahi Kasei Group (asahi-kasei.co.jp) is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 29,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries.
Copyright © 2014 ZOLL Medical Corporation. All rights reserved. IVTM, LifeVest, Real CPR Help, R Series, See-Thru CPR, Thermogard XP, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All product names are the property of their respective owners.
i Halkin, A et al. Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: CADILLAC Risk Score. JACC 2005;45:1397 1405.
ii Stone, G et al. Prevention of Sudden Cardiac Arrest Post PTCA in High-Risk Patients. theheart.org/article/1202823.do (April 2011).